Caspa200 mg/5 ml

An azole antifungal drug is Caspa 200 mg/5 ml. The following fungal infections are recommended for use in individuals 12 years of age and older. Aspergillosis invasive Disseminated candidiasis and candidemia (nonneutropenic) in the skin, abdomen, kidney, bladder wall, and wounds Esophageal candidiasis Severe infections brought on by Fusarium species include Fusarium solani Scedosporium apiospermum Those who are resistant to or intolerant of alternative treatments.

Other Antifungal preparations

The major mechanism of action of Caspa 200 mg/5 ml is the suppression of 14 alpha-lanosterol demethylation, which is mediated by fungal cytochrome P450 and is a crucial step in the manufacture of fungal ergosterol. The buildup of 14 alpha-methyl sterols and subsequent loss of ergosterol from the fungal cell membrane may be what gives Caspa 200 mg/5 ml its antifungal properties. It has been demonstrated that Caspa 200 mg/5 ml is more selective for cytochrome P-450 enzymes found in fungi than for other cytochrome P-450 enzyme systems found in mammals.

Oral-Caspa 200 mg/5 ml tablet and powder for suspension are to be taken at least one hour before or one hour following a meal At or over 40 kg body weight: Loading dose regimen is 400 mg or 10 ml every 12 hours (for the first 24 hours) and maintenance dose (after first 24 hours) is 200 mg or 5 ml twice daily. Below 40 Kg body weight: Loading dose regimen is 200 mg or 5 ml every 12 hours (for the first 24 hours) and maintenance dose (after first 24 hours) is 100 mg or 2.5 ml twice daily. Or, as directed by the registered physician. Injection-Invasive Aspergillosisd : Loading dose: 6 mg/kg 12 hourly for the first 24 hours. Maintenance Dose: 4 mg/kg 12 hourly. Candidemia in nonneutropenic patients and other deep tissue Candida infections: Loading dose: 6 mg/kg 12 hourly for the first 24 hours. Maintenance Dose: 3-4 mg/kg 12 hourly. Scedosporiosis and Fusariosis: Loading dose: 6 mg/kg 12 hourly for the first 24 hours. Maintenance Dose: 4 mg/kg 12 hourly.

It is recommended to take Caspa 200 mg/5 ml film-coated pills at least one hour before or one hour after a meal. Depending on the patient's clinical and mycological response, the length of the treatment should be as brief as possible. Caspa 200 mg/5 ml exposure longer than 180 days (6 months) must be carefully weighed against the risks and benefits. prevention in both adults and children Beginning the day of the transplant, prophylaxis can be given for up to 100 days. Depending on the risk of acquiring invasive fungal infection (IFI), as indicated by neutropenia or immunosuppression, prophylaxis should be as brief as possible. In the event of ongoing immunosuppression or graft against host disease, it may only be continued for up to 180 days following transplantation (GvHD).

Inhibitors and inducers of CYP3A4, CYP2C9, and CYP2C19: Caspa 200 mg/5 ml dosage should be changed, and side effects or ineffectiveness should be watched for. Drugs that are CYP3A4, CYP2C9, and CYP2C19 substrates may have higher concentrations and activities when taken with Caspa 200 mg/5 ml. Decrease these other drugs' dosages and keep an eye out for any negative effects Raise the maintenance dose of oral and intravenous Caspa 200 mg/5 ml when also taking phenytoin or efavirenz

Known sensitivity to the drug's active ingredient, Caspa 200 mg/5 ml, or any other ingredient- Risk of major adverse effects necessitates avoiding co-administration of sirolimus with terfenadine, astemizole, cisapride, pimozide, or quinidine. Rifampin, carbamazepine, long-acting barbiturates, efavirenz, ritonavir, rifabutin, ergot alkaloids, and St. John's Wort should not be administered together due to the possibility of efficacy loss.

Abdominal pain, anemia, impaired vision, headaches, chest pain, nausea, and diarrhea are the most frequent adverse effects.

There aren't enough facts about Caspa 200 mg/5 ml use during pregnancy. If the potential risk to the fetus is not clearly outweighed by the benefit to the mother, Caspa 200 mg/5 ml should not be administered during pregnancy. There hasn't been any research done on Caspa 200 mg/5 ml excretion into breast milk. Following the start of Caspa 200 mg/5 ml treatment, breastfeeding must be discontinued.

The benefit-risk balance of long-term exposure (treatment or prophylaxis) of more than 180 days must be carefully weighed. Long-term Caspa 200 mg/5 ml therapy has been linked to reports of squamous cell carcinoma of the skin (SCC).

There is no data found about overdose of Caspa 200 mg/5 ml.

Keep out of children's reach. Keep away from light in a dry area with a temperature below 25°C. Caspa 200 mg/5 ml powder for suspension should be kept between 2° and 8°C.

Older people do not require a dosage change. Pediatric population: It is unknown whether Caspa 200 mg/5 ml is safe and effective for use in children under the age of two. Renal impairment: Renal impairment has no impact on the pharmacokinetics of Caspa 200 mg/5 ml taken orally. As a result, the oral dosage is unaffected in individuals with mild to severe renal impairment. Haemodialysis clearance for Caspa 200 mg/5 ml is 121 ml/min. Caspa 200 mg/5 ml is not enough removed by a 4-hour hemodialysate to require a dose change. Hepatic impairment: In patients receiving Caspa 200 mg/5 ml who have mild to severe hepatic cirrhosis (Child-Pugh A and B), it is advised to utilize the regular loading dosage regimens but to cut the maintenance dose in half. Patients with severe chronic hepatic cirrhosis have not been examined with Caspa 200 mg/5 ml. In individuals with abnormal liver function tests (aspartate transaminase [AST], alanine transaminase [ALT], alkaline phosphatase [ALP], or total bilirubin >5 times the upper limit of normal), there is minimal information on the safety of Caspa 200 mg/5 ml. Only use Caspa 200 mg/5 ml in patients with severe hepatic impairment if the benefit justifies the potential risk because it has been linked to increases in liver function tests and clinical symptoms of liver damage, such as jaundice. Drug toxicity in patients with a severe hepatic impairment needs to be closely watched.

Other Antifungal preparations

A triazole antifungal drug called Caspa 200 mg/5 ml is used to treat severe fungi infections. By preventing CYP450-dependent 14-alpha sterol demethylase from functioning, Caspa 200 mg/5 ml binds and prevents the formation of ergosterol. Ergosterol levels in the membrane of fungal cells decrease as a result of the suppression of 14-alpha sterol demethylase.

There is no sufficient, carefully regulated research on pregnant women. Only if the possible benefit outweighs the potential risk to the fetus should it be taken during pregnancy.

The effectiveness for children under the age of 12 has not been established.